OPEN ACCESS

Pneumocystis in metastatic lung cancer, a pragmatic approach in support of prophylaxis

David Luque Paz,¹ Stephane Jouneau,² Pierre Tattevin,¹ Charles Ricordel ²

¹Infectious Diseases and Intensive Care Unit, CHU Rennes, Rennes, France
²Department of Respiratory Medicine, Centre Hospitalier Universitaire de Rennes, Rennes, France

Correspondence to
 Dr Charles Ricordel;
 charles.ricordel@chu-rennes.fr

Accepted 7 May 2021

SUMMARY

Lung cancer prognosis has improved in the last decade, including in patients with brain metastasis. However, few of these patients who receive corticosteroids have a primary prophylaxis for *Pneumocystis jirovecii* pneumonia (PJP). We report the case of an 80-year-old man diagnosed with non-small cell lung cancer and concomitant symptomatic brain metastases, treated with 50 mg/day of prednisolone without any prophylaxis, who presented an acute PJP. After 72 hours of unsuccessful treatment of PJP, the patient died. In our review of this case and the existing literature, we emphasise the importance of a wide use of prophylaxis for PJP, especially in advanced lung cancer treated with corticosteroid therapy. We discuss this issue and report current evidence for primary prophylaxis by trimethoprim-sulfamethoxazole.

BACKGROUND

Human pneumocystosis is a fungal infection caused by *Pneumocystis jirovecii*, a cosmopolitan and opportunistic ubiquitous fungus. *P. jirovecii* pneumonia (PJP) is potentially lethal, developing mainly in the lungs of profoundly immunocompromised patients. HIV infection, organ transplants and haematological malignancies are well-defined risk factors.^{1 2}

A review of the literature provided arguments to consider a pathophysiological association between *P. jirovecii* and the use of corticosteroids, and American Thoracic Society (ATS) guidelines recommend prophylaxis when prednisone doses exceed 20 mg/day for longer than 1 month.³

We present a case of a lethal PJP in a patient with metastatic lung cancer who received corticosteroids without prophylaxis.

CASE PRESENTATION

In August 2015, an 83-year-old HIV-negative, non-smoker Caucasian man was diagnosed with T3N2M0 small cell lung carcinoma. He went into complete remission after six cycles of carboplatin/etoposide and thoracic radiation (30 Gy with daily fractions of 3 Gy).

In December 2016, a stage I (pT1N0M0) right lower lobe lung adenocarcinoma was discovered and treated with lobectomy. The tumour had no EGFR, BRAF or KRAS mutation and no ALK, ROS1, RET rearrangement; only a copy number variation of MET gene (two to three copies). In April 2017, a neurological impairment revealed a frontal brain metastasis. The patient was treated with radiotherapy associated with methylprednisolone

initially at 100 mg/day and then reduced to 50 mg/day.

In June 2017, he presented dry cough and shortness of breath associated with self-reported fever. Two days after the first symptoms, he was admitted to hospital. At admission, he had fever (38.2°C), blood pressure was 108/61 mm Hg, regular pulse of 79 bpm, respiration of 18 cycles/min, and 95% SpO₂ with 2 L/min of oxygen supplementation. There was no recent chemotherapy, and no immunosuppressive treatment other than corticosteroids.

INVESTIGATIONS

Blood laboratory tests revealed no cytopenia: haemoglobin concentration 129 g/L, platelet count $244\ 000 \times 10^9/L$, white cell count $6400/mm^3$, including neutrophil count $3900/mm^3$. There was no renal dysfunction with an estimated glomerular filtration rate of $>60 mL/min$. Chest CT scan showed bilateral excavated nodules evoking lung abscesses, associated with diffuse bilateral ground-glass opacities (figure 1). A bronchoalveolar lavage (BAL) was immediately performed with good tolerance, for bacteriological and mycological analyses. Blood culture and serum galactomannan antigen were negative.

DIFFERENTIAL DIAGNOSIS

A posteriori, BAL results revealed the presence of *P. jirovecii* (with Gomori-Grocott staining, indirect immunofluorescence and positive *Pneumocystis* PCR at the 21st cycle of amplification), as well as a few colonies of *Aspergillus fumigatus* in culture, *Actinomyces odontolyticus* (10^5 UFC/mL) in culture and *Nocardia nova* susceptible to trimethoprim-sulfamethoxazole (TMP-SMX).⁴

To explain the acute respiratory failure, we discarded the role of *A. odontolyticus*, which is probably a contamination during the BAL procedure. Images of lung abscesses are compatible with *N. nova*, but nocardiosis would not explain the rapid clinical degradation. *A. fumigatus* could be implicated in respiratory failure, but the patient had no neutropenia and a negative *A. fumigatus* PCR in BAL, making the possibility of rapidly lethal invasive aspergillosis less likely.

The association of diffuse bilateral ground-glass opacities, very low cycle threshold value of *Pneumocystis* PCR in BAL, a positive direct examination and a deep hypoxaemia progressing into severe acute respiratory failure are solid arguments to attribute the death of the patient to a PJP, rather than other coinfections.

© BMJ Publishing Group Limited 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Luque Paz D, Jouneau S, Tattevin P, et al. *BMJ Case Rep* 2021;**14**:e232895. doi:10.1136/bcr-2019-232895

Figure 1 Chest CT scan with bilateral excavated nodules evoking lung abscesses, associated with diffuse bilateral ground-glass opacities.

TREATMENT

First, the patient was treated with ceftriaxone and rovamycin as recommended for community-acquired pneumonia with comorbidities and severity criteria. After the chest CT, intravenous voriconazole and TMP–SMX treatment was started. Corticosteroids were maintained as adjuvant therapy of hypoxaemic PJP.

OUTCOME AND FOLLOW-UP

His clinical situation worsened on a respiratory level with increasing oxygen needs. Despite 48 hours of probabilistic treatment, his respiratory failure became critical. On arterial blood gas, he presented an extremely severe hypoxaemia despite oxygen supply (flow rate 15 L/min) with a PaO_2 measured at 39 mm Hg. The patient died on day 3.

DISCUSSION

In patients with lung cancer, especially with brain metastasis, corticosteroids are commonly prescribed. Life expectancy is limited to a few months or years in most cases, and physicians do not prescribe chemoprophylaxis against *Pneumocystis* spp. A retrospective study showed that fewer patients with solid tumours (3.9%) received prophylaxis compared with patients with haematological malignancies (63.6%).⁵

Lung cancer is at low risk of PJP (<25 cases/100 000 patient-year) like other solid tumours, excluding central nervous system cancer.⁶ But for patients having solid cancer and being treated by corticosteroids, the incidence of PJP rises to 1.3%.⁷ Furthermore, PJP is usually more abrupt and fulminant⁸ among patients with neoplastic disease, and its mortality rate is much higher, approaching 50%,^{7,9} and a significant risk factor of mortality with an OR=2.66. In different studies, 55%–87% of patients with PJP had previously used corticosteroids, and 18%–31% had a solid tumour.^{9,10} The most important predisposing factor for developing PJP is the use of steroids, even at a low dose (equivalent to ≥ 20 mg/day prednisone for ≥ 1 month).^{11,12} ATS guidelines recommend prophylaxis when prednisone doses exceed 20 mg/day for longer than 1 month.

Recent guidelines¹³ and two general reviews^{14,15} recommend prophylaxis for patients with solid cancer receiving prolonged, high-dose corticosteroid treatment (16–25 mg of prednisolone/

day or ≥ 4 mg dexamethasone daily for ≥ 4 weeks) regardless of the stage of malignancy.

Concerning the toxicity of TMP–SMX, 85% of the patients do not experience any toxic effects.¹⁶ So, when steroids are prescribed for a patient with cancer, especially in metastatic diseases, we prioritise a pragmatic attitude: start a prophylaxis if survival exceeds 3 months.

Learning points

- ▶ Corticosteroids are a major risk factor of *Pneumocystis jirovecii* pneumonia (PJP), adding to the risk of PJP in lung cancer.
- ▶ Guidelines recommend PJP prophylaxis by trimethoprim–sulfamethoxazole (TMP–SMX) when dose >20 mg/day.
- ▶ Side effects occur in 15% of cases, and discontinuation of the prophylaxis is required in 3% of patients treated.
- ▶ Our pragmatic proposal: start a primary prophylaxis if survival exceeds 3 months, and eventually discuss alternatives in case of TMP–SMX intolerance.

Contributors DLP and PT contributed to conception and design of the manuscript. PT and SJ were responsible for the literature review. DLP was responsible for clinical data collection. DLP and CR were responsible for figures. All authors were responsible for manuscript editing and final approval of the article. CR takes responsibility for the paper as a whole.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Next of kin consent obtained.

Provenance and peer review Not commissioned; externally peer-reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Charles Ricordel <http://orcid.org/0000-0001-6160-2732>

REFERENCES

- Radhi S, Alexander T, Ukwu M, *et al.* Outcome of HIV-associated *Pneumocystis* pneumonia in hospitalized patients from 2000 through 2003. *BMC Infect Dis* 2008;8:118.
- Maertens J, Cesaro S, Maschmeyer G, *et al.* ECIL guidelines for preventing *Pneumocystis jirovecii* pneumonia in patients with haematological malignancies and stem cell transplant recipients. *J Antimicrob Chemother* 2016;71:2397–404.
- Limper AH, Knox KS, Sarosi GA, *et al.* An official American thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. *Am J Respir Crit Care Med* 2011;183:96–128.
- Schlager R, Fisher MA, Hanson KE. Susceptibility profiles of *Nocardia* isolates based on current taxonomy. *Antimicrob Agents Chemother* 2014;58:795–800.
- Worth LJ, Dooley MJ, Seymour JF, *et al.* An analysis of the utilisation of chemoprophylaxis against *Pneumocystis jirovecii* pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer Hospital. *Br J Cancer* 2005;92:867–72.
- Fillatre P, Decaux O, Jouneau S, *et al.* Incidence of *Pneumocystis jirovecii* pneumonia among groups at risk in HIV-negative patients. *Am J Med* 2014;127:1242.e11–17.
- Yale SH, Limper AH. *Pneumocystis carinii* pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. *Mayo Clin Proc* 1996;71:5–13.
- Gripaldo R, Lippmann ML. *Pneumocystis* pneumonia in HIV-negative patients: a review of the literature. *Clin Pulmonary Med* 2012;19:5–13.
- Sepkowitz KA, Brown AE, Telzak EE, *et al.* *Pneumocystis carinii* pneumonia among patients without AIDS at a cancer Hospital. *JAMA* 1992;267:832–7.
- Roblot F, Godet C, Le Moal G, *et al.* Analysis of underlying diseases and prognosis factors associated with *Pneumocystis carinii* pneumonia in immunocompromised HIV-negative patients. *Eur J Clin Microbiol Infect Dis* 2002;21:523–31.

- 11 Schoovaerts K, Dirix L, Rutten A, *et al.* *Pneumocystis jirovecii* pneumonia (PJP) in non-HIV immunocompromised individuals. *Acta Clin Belg* 2017;72:413–6.
- 12 Barbounis V. Should patients with malignancy receive chemoprophylaxis against *Pneumocystis jirovecii* pneumonia? *Nat Clin Pract Oncol* 2005;2:490–1.
- 13 Cooley L, Dendle C, Wolf J, *et al.* Consensus guidelines for diagnosis, prophylaxis and management of *Pneumocystis jirovecii* pneumonia in patients with haematological and solid malignancies, 2014. *Intern Med J* 2014;44:1350–63.
- 14 Rouyer M, Stoclin A, Blanc F-X. [Pneumocystis pneumonia in HIV-negative adults]. *Rev Mal Respir* 2015;32:985–90.
- 15 Roux A, Gonzalez F, Roux M, *et al.* Update on pulmonary *Pneumocystis jirovecii* infection in non-HIV patients. *Med Mal Infect* 2014;44:185–98.
- 16 Green H, Paul M, Vidal L, *et al.* Prophylaxis of *Pneumocystis pneumonia* in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. *Mayo Clin Proc* 2007;82:1052–9.

Copyright 2021 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit <https://www.bmj.com/company/products-services/rights-and-licensing/permissions/>
BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.

Become a Fellow of BMJ Case Reports today and you can:

- ▶ Submit as many cases as you like
- ▶ Enjoy fast sympathetic peer review and rapid publication of accepted articles
- ▶ Access all the published articles
- ▶ Re-use any of the published material for personal use and teaching without further permission

Customer Service

If you have any further queries about your subscription, please contact our customer services team on +44 (0) 207111 1105 or via email at support@bmj.com.

Visit casereports.bmj.com for more articles like this and to become a Fellow